Table 1 | Selected PCSK9 inhibitors

Drug	Developers	Description	Status
Praluent (alirocumab)	Regeneron Pharmaceuticals, Sanofi	Human IgG1 mAb	First FDA approval 24 July 2015
Repatha (evolocumab)	Amgen	Human IgG2 mAb	First FDA approval 27 August 2015
Inclisiran	The Medicines Company, Alnylam Pharmaceuticals	*N*-acetylgalactosamine-conjugated siRNA	FDA filing planned for Q4 2019
AK102	Akeso Biopharma (Zongshan, China), Dawnrays Pharma (Suzhou, China)	Humanized IgG2 mAb	Phase 2
AT04	Affiris (Vienna)	Recombinant-peptide vaccine that mimics the N-terminal domain of PCSK9 protein	Phase 1
PF-06446846	Pfizer	Small molecule that inhibits PCSK9 translation through selective ribosome stalling	Preclinical
P-21	Shifa Biomedical	Small molecule that blocks LDL-receptor binding to PCSK9	Preclinical
NYX-330	Nyrada	Small-molecule PCSK9 inhibitor	Preclinical
Undisclosed	Draupnir Bio (Aarhus, Denmark)	Small-molecule PCSK9 inhibitor	Preclinical

Sources: FDA, ClinicalTrials.gov, PubMed and company websites.

PCSK9 with a variety of small-molecule approaches (Table 1). Even if the poor commercial performance of early market entrants has slowed the initial adoption of the first generation of drugs to embody genomics-driven insights into the biology of cardiovascular disease, there is a much wider promise attached to this form of intervention — and there could be a whole lot more to come. ❐

Cormac Sheridan
Dublin, Ireland

Published online: 3 December 2019
https://doi.org/10.1038/s41587-019-0351-4

Around the world in a month



Credit: Map: © iStockphoto; Flags: pop_jop / DigitalVision Vectors / Getty

Published online: 3 December 2019
https://doi.org/10.1038/s41587-019-0348-z